Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

823
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.4K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.2K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fosinopril: HIV-Associated Nephropathy (HIVAN).

Hospital pharmacy·2024
Same author

Idarucizumab.

Hospital pharmacy·2024
Same author

Fentanyl Iontophoretic Transdermal System.

Hospital pharmacy·2024
Same author

Fifty Years of Publication: Hospital Pharmacy Anniversary.

Hospital pharmacy·2024
Same author

Rolapitant.

Hospital pharmacy·2024
Same author

Zafirlukast: Chronic Urticaria.

Hospital pharmacy·2016
Same journal

Intrapleural Tissue Plasminogen Activator With or Without Dornase Alfa: A Multicenter Retrospective Cohort Study.

Hospital pharmacy·2026
Same journal

Stability of Diluted Intravenous Metronidazole in 0.9% Sodium Chloride.

Hospital pharmacy·2026
Same journal

Response to Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Significant Published Articles in 2025 for Pharmacy Nutrition Support Practice.

Hospital pharmacy·2026
Same journal

Comment on "Early Versus Later Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".

Hospital pharmacy·2026
Same journal

Comparison of Cystatin C-Based and Serum Creatinine-Based Renal Function Estimates Against Timed Urine Collection in Critically Ill Patients.

Hospital pharmacy·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

7.3K

Prazosin: benign prostatic hyperplasia.

Joyce A Generali1, Dennis J Cada2

  • 1Editor-in-Chief, Hospital Pharmacy, and Director, Drug Information Center, Kansas University Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160,

Hospital Pharmacy
|January 15, 2014
PubMed
Summary
This summary is machine-generated.

This guide helps healthcare professionals quickly find studies on unapproved drug uses (off-label drugs). It aids in determining if these uses are rational for patient care, referencing full literature for informed decisions.

More Related Videos

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

16.6K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.2K

Related Experiment Videos

Last Updated: May 4, 2026

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

7.3K
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

16.6K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.2K

Area of Science:

  • Hospital Pharmacy
  • Clinical Pharmacology

Background:

  • Off-label drug use refers to prescribing medications for conditions not approved by the US Food and Drug Administration (FDA).
  • Practitioners require reliable resources to navigate the complexities of unapproved drug indications.

Purpose of the Study:

  • To introduce "Off-Label Drug Facts," a publication designed for healthcare professionals.
  • To provide a resource for identifying and evaluating published literature on off-label drug uses.

Main Methods:

  • The feature extracts information from "Off-Label Drug Facts."
  • It guides users in literature identification and assessment of off-label drug use rationality.
  • References are provided for further in-depth information.

Main Results:

  • Clinicians can efficiently access studies on specific off-label drug applications.
  • The resource supports evidence-based decision-making for patient care scenarios involving unapproved drug uses.

Conclusions:

  • "Off-Label Drug Facts" serves as a valuable tool for practitioners seeking information on unapproved drug indications.
  • It facilitates informed clinical judgment by providing access to relevant literature and study evaluations.